bibloc 2,5 mg tabletki powlekane
inpharm sp. z o.o. - bisoprololi fumaras - tabletki powlekane - 2,5 mg
bibloc 1,25 mg tabletki powlekane
inpharm sp. z o.o. - bisoprololi fumaras - tabletki powlekane - 1,25 mg
bibloc 1,25 mg tabletki powlekane
inpharm sp. z o.o. - bisoprololi fumaras - tabletki powlekane - 1,25 mg
runrapiq 300 mg proszek do sporządzania roztworu do infuzji
amomed pharma gmbh - landiololi hydrochloridum - proszek do sporządzania roztworu do infuzji - 300 mg
runrapiq 20 mg/2 ml koncentrat do sporządzania roztworu do wstrzykiwań
amomed pharma gmbh - landiololi hydrochloridum - koncentrat do sporządzania roztworu do wstrzykiwań - 20 mg/2 ml
runrapiq 600 mg proszek do sporządzania roztworu do infuzji
amomed pharma gmbh - landiololi hydrochloridum - proszek do sporządzania roztworu do infuzji - 600 mg
fexofenadine hydrochloride cipla 120 mg tabletki powlekane
cipla europe nv - fexofenadini hydrochloridum - tabletki powlekane - 120 mg
fexofenadine hydrochloride cipla 180 mg tabletki powlekane
cipla europe nv - fexofenadini hydrochloridum - tabletki powlekane - 180 mg
tysabri
biogen netherlands b.v. - natalizumab - stwardnienie rozsiane - selektywne leki immunosupresyjne - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 i 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
fingolimod mylan
mylan ireland limited - fingolimod jest chlorowodorek - stwardnienie rozsiane, Рецидивно-znika - leki immunosupresyjne - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 i 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.